Bay Area biotech giant Gilead to lay off 108 workers in Redwood City

Gilead Sciences plans to lay off 108 workers in Redwood City, the latest job cuts by one of the Bay Area's biggest biotech companies.

The permanent layoffs are scheduled to take effect June 30 at 800 Bridge Parkway, according to a notice filed last week with the California Employment Development Department.

"This is part of the integration following the close of the Arcellx acquisition," Gilead said in a statement to the Chronicle on Tuesday. "These decisions are never taken lightly, and our focus is on supporting employees through this transition with transparency and respect."

Gilead completed its acquisition of Arcellx, a biotechnology company focused on cancer cell therapies, earlier this year. The deal expanded Gilead's cell therapy business, an area the company has been building through its Kite subsidiary.

The Foster City company is one of the Bay Area's most prominent biotech firms, with a large local workforce and a global business built around treatments for HIV, viral hepatitis, COVID-19 and cancer. It operates in more than 35 countries.

The Redwood City cuts follow multiple rounds of layoffs by Gilead in California over the past year. In April 2025, the company said it would lay off 149 workers at its Foster City headquarters, largely affecting managers and directors across several divisions.

Gilead has also cut jobs at its Oceanside campus in San Diego County, where 34 layoffs were scheduled to take effect March 27, according to a separate notice. The Oceanside site supports clinical manufacturing and process development, according to the company.

The new layoffs come as Gilead continues to highlight its drug pipeline and court investors.

In a May 1 announcement, the company said executives would present at four healthcare investor conferences in May and June, including events hosted by BofA Securities, RBC Capital Markets, Bernstein and Goldman Sachs.

Gilead has recently promoted its HIV portfolio, including lenacapavir, a twice-yearly injectable HIV prevention drug approved by the Food and Drug Administration in 2025 under the brand name Yeztugo.

Despite the reductions, Gilead remains one of the region's largest biotech employers. The company had more than 8,000 workers in Foster City, including contractors, according to the Bay Area Council Economic Institute, and more than 18,000 employees worldwide.

Copyright 2026 Tribune Content Agency. All Rights Reserved.